This inventor holds 3 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2009-2017.
Location History:
- Celje, SI (2009 - 2014)
- Ljubljana, SI (2017)
Company Filing History:
Years Active: 2009-2017
Title: Tanja Rozman Peterka: Innovator in Pharmaceutical Composition
Introduction
Tanja Rozman Peterka is a prominent inventor based in Celje, Slovenia. She has made significant contributions to the field of pharmaceuticals, particularly in the development of stable compositions that enhance the efficacy of medications. With a total of 3 patents to her name, her work is recognized for its innovative approach to drug formulation.
Latest Patents
Among her latest patents is a pharmaceutical composition that comprises an ester of 4-(1-hydroxy-1-methylethyl)-2 propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid. This composition is characterized by its stability when exposed to 75% relative humidity at 40°C in an open dish for one month, ensuring that the total amount of related substances does not increase by more than 1%. Another notable patent is a stable pharmaceutical composition comprising erythropoietin (EPO) that is stabilized with PVP, which addresses the challenges of maintaining the stability of this important therapeutic protein.
Career Highlights
Tanja Rozman Peterka has been instrumental in advancing pharmaceutical research and development. Her work at Lek Pharmaceuticals D.d. has positioned her as a key player in the industry, where she continues to innovate and contribute to the field of medicine.
Collaborations
Throughout her career, Tanja has collaborated with talented individuals such as Andreja Vukmirovic and Jelka Svetek, enhancing the scope and impact of her research.
Conclusion
Tanja Rozman Peterka's contributions to pharmaceutical compositions demonstrate her commitment to innovation in medicine. Her patents reflect a deep understanding of drug stability and efficacy, making her a valuable asset to the pharmaceutical industry.